It was also proven that blocking the activity of EGFR has an antitumor effect on the development of HCC29, whereas the AKT signaling pathway has been firmly established as a major determinant of HCC occurrence and might be the target of specific inhibiting therapies30, 31. This evidence concerns the gene AKT1 and hepatocellular carcinoma.